2024-01-23 10:30:09 ET
The timing couldn't be odder for Autolus Therapeutics (AUTL). Just when the FDA agreed to review its CAR-T cancer therapy obe-cel and set an action date, the regulator also said separately that a serious warning had to be added to the prescribing information of CAR-T cancer therapies. AUTL has lost ~20% in the last few trading sessions since its Jan 11th close of $7.29....
Read the full article on Seeking Alpha
For further details see:
SA Analysts Comment On FDA Seeking Boxed Warning For CAR-T Cancer Therapies, Related Impact On AUTL